Implantica (IMP) Q1 2025 earnings summary

Executive summary

• Net sales rose 25% year-over-year to EUR 745,000, driven by RefluxStop adoption in Europe and targeting a vast market of 1 billion acid reflux sufferers.

• Operating loss (EBIT) narrowed by 41% to EUR 4.2 million, reflecting lower R&D and patent costs.

• The company is developing an eHealth platform and other implantable devices, supported by a strong patent portfolio and future product plans.

• FDA feedback on RefluxStop PMA was positive, with key modules accepted and U.S. launch on track.

• Over 1,200 RefluxStop procedures completed globally, with growing demand and new hospital adoptions.

Financial highlights

• Net sales for Q1 2025 reached EUR 745,000, a 25% increase year-over-year, driven by new and more active centers.

• Adjusted gross margin rose to 97% from 92% in the prior year period.

• Operating loss decreased by 41% to EUR 4.2 million, reflecting lower R&D and patent costs.

• Cash and short-term investments stood at EUR 60.3 million at March-end, with no interest-bearing debt.

• R&D costs fell 64% to EUR 1,576 thousand due to lower FDA submission expenses.

Outlook and guidance

• U.S. FDA approval for RefluxStop is expected in late 2025, with module three filing imminent and a normal review timeline suggesting possible approval by year-end.

• U.S. launch will target 50 centers of excellence, leveraging favorable reimbursement and existing codes.

• Targeting a 25-30% price premium in the U.S., with a price point of $7,800 per procedure.

• European expansion continues, with 1,200 surgeries performed and nearly 50 hospitals engaged.

• Strategic focus on finalizing PMA, expanding European presence, and launching pivotal RCTs.